Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 1
1989 2
1990 13
1991 11
1992 5
1993 4
1994 2
1995 1
1997 1
1999 1
2001 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

42 results

Results by year

Filters applied: . Clear all
Page 1
Sezolamide: additivity to timolol twice daily.
Gunning F, Béchetoille A, Lippa EA, Pfeiffer N, Gerling J, Holder D, Clineschmidt C, Buntinx A, Brunner-Ferber FL, Grehn F, et al. Gunning F, et al. Eye (Lond). 1992;6 ( Pt 5):525-9. doi: 10.1038/eye.1992.111. Eye (Lond). 1992. PMID: 1286720 Clinical Trial.
Sezolamide, a potent topical carbonic anhydrase inhibitor previously known as MK-417, was studied to determine its ocular hypotensive activity in patients with elevated intraocular pressure while on continuing therapy with topical timolol. ...At hours 1, 2, 4 and 8 the red …
Sezolamide, a potent topical carbonic anhydrase inhibitor previously known as MK-417, was studied to determine its ocular hypotensive …
MK-507 versus sezolamide. Comparative efficacy of two topically active carbonic anhydrase inhibitors.
Lippa EA, Schuman JS, Higginbotham EJ, Kass MA, Weinreb RN, Skuta GL, Epstein DL, Shaw B, Holder DJ, Deasy DA, et al. Lippa EA, et al. Ophthalmology. 1991 Mar;98(3):308-12; discussion 312-3. doi: 10.1016/s0161-6420(91)32295-4. Ophthalmology. 1991. PMID: 2023750 Clinical Trial.
MK-507 was given every 8 or 12 hours, sezolamide every 8 hours, or placebo every 8 or 12 hours for 4 days. Both drugs lowered intraocular pressure (IOP) substantially. MK-507 was somewhat more active than sezolamide, with a peak mean IOP reduction of 26.2% for MK-50 …
MK-507 was given every 8 or 12 hours, sezolamide every 8 hours, or placebo every 8 or 12 hours for 4 days. Both drugs lowered intraoc …
Two topical carbonic anhydrase inhibitors sezolamide and dorzolamide in Gelrite vehicle: a multiple-dose efficacy study.
Gunning FP, Greve EL, Bron AM, Bosc JM, Royer JG, George JL, Lesure P, Sirbat D. Gunning FP, et al. Graefes Arch Clin Exp Ophthalmol. 1993 Jul;231(7):384-8. doi: 10.1007/BF00919645. Graefes Arch Clin Exp Ophthalmol. 1993. PMID: 8406063 Clinical Trial.
On day 6 the peak mean percentage decrease in IOP from baseline occurred 4 h after the dose of dorzolamide (22.1%) and 6 h after the dose of sezolamide (21.3%). There were no significant differences between 2% dorzolamide and 1.8% sezolamide at any time point, altho …
On day 6 the peak mean percentage decrease in IOP from baseline occurred 4 h after the dose of dorzolamide (22.1%) and 6 h after the dose of …
[Additive effect of timolol and the local carbonic anhydrase inhibitor MK-417 (sezolamide)].
Pfeiffer N, Greve E, Béchetoille A, Lippa EA, Jaquet-Müller F, Gunning F, Gerling J, Grehn F. Pfeiffer N, et al. Fortschr Ophthalmol. 1991;88(6):846-7. Fortschr Ophthalmol. 1991. PMID: 1794818 Clinical Trial. German.
MK-417 (sezolamide) is a topically active carbonic anhydrase inhibitor. The effect of additional treatment with sezolamide 1.8% twice daily to patient already receiving timolol 0.5% twice daily was investigated. ...Thus, sezolamide may be a useful addition to …
MK-417 (sezolamide) is a topically active carbonic anhydrase inhibitor. The effect of additional treatment with sezolamide 1.8 …
Multiple-dose efficacy comparison of the two topical carbonic anhydrase inhibitors sezolamide and MK-927.
Bron A, Lippa EA, Gunning F, Bénichou C, Lesure P, Sirbat D, Royer J, Flament J, Clineschmidt C, Panebianco D, et al. Bron A, et al. Arch Ophthalmol. 1991 Jan;109(1):50-3. doi: 10.1001/archopht.1991.01080010052031. Arch Ophthalmol. 1991. PMID: 1987948 Clinical Trial.
Both compounds demonstrated significant lowering of intraocular pressure at 8 AM, 12 hours following the evening dose, and through 10 and 6 hours following the 8 AM dose for sezolamide and MK-927, respectively. Morning trough (evening) activity as measured by mean percent …
Both compounds demonstrated significant lowering of intraocular pressure at 8 AM, 12 hours following the evening dose, and through 10 and 6 …
Absence of metabolic effects of the topical carbonic anhydrase inhibitors MK-927 and sezolamide during two-week ocular administration to normal subjects.
Buclin T, Biollaz J, Lippa EA, Brunner-Ferber F, van Melle G, Munafo A, Clineschmidt C, Schelling JL. Buclin T, et al. Clin Pharmacol Ther. 1991 Jun;49(6):665-73. doi: 10.1038/clpt.1991.84. Clin Pharmacol Ther. 1991. PMID: 2060255 Clinical Trial.
Potential systemic effects of the racemic carbonic anhydrase inhibitor MK-927 and its S-enantiomer, sezolamide hydrochloride, after topical ocular administration were investigated in a double-masked, randomized, placebo-controlled study in 16 healthy volunteers. ...For 14 …
Potential systemic effects of the racemic carbonic anhydrase inhibitor MK-927 and its S-enantiomer, sezolamide hydrochloride, after t …
Topical carbonic anhydrase inhibitors.
Kass MA. Kass MA. Am J Ophthalmol. 1989 Mar 15;107(3):280-2. doi: 10.1016/0002-9394(89)90313-9. Am J Ophthalmol. 1989. PMID: 2923154 No abstract available.
42 results